The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms

Abdominal Aortic Aneurysms Clinical Trial

Official title:

The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02048514
• Other study ID #: N09-01
• Status: Completed
• Phase: N/A
• Start date: December 2008
• Est. completion date: December 2017

Study information

• Verified date: March 2021
• Source: Endologix
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical study is to evaluate the safety and device performance of the Nellix® EndoVascular Aneurysm Sealing System (Nellix System) for the treatment of infrarenal abdominal aortic aneurysms.

Description:

This is a multicenter, multi-country prospective, single-arm, non-randomized clinical trial. The comparative control arm is a combination of patient data drawn from the abdominal aortic aneurysms (AAA) open surgical control arms of four commercially approved AAA devices as part of the Society of Vascular Surgeons. Patients enrolled in this study will be pre-screened and have a diagnosis of an infrarenal AAA with or without the need for treatment of iliac artery aneurysm, are candidates for endovascular repair, and meet the eligibility criteria. Patients enrolled in the study will participate in follow-up visits 31 days, 6 months and at 1 year following the index procedure. At the follow-up visits there will be a clinical assessment, blood collection, and abdominal CT imaging of the patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years of age
• Informed consent form understood and signed and patient agrees to all follow-up visits
• Is able and willing to comply with clinical follow-up requirements for one year
• Is able and willing to undergo Contrast-Enhanced Spiral CT scans
• Is a candidate for endovascular repair of an infrarenal aortic aneurysm with or without an iliac aneurysm with at least one of the following;

1. aneurysm = 4.5 cm in diameter, or

2. aneurysm is twice the diameter of the normal infrarenal aorta, or

3. aneurysm is growing at a rate of = 10 % per year

• Non-aneurysmal aortic neck length = 5mm below the most inferior renal artery
• Proximal aortic neck diameter between 16 and 36mm
• Aortic neck angulation to the sac = 60
• Common iliac artery diameter 8 to 35mm bilaterally
• Aneurysm blood lumen diameter = 60mm
• Iliac and femoral arteries suitable for endovascular access with the Nellix System

Exclusion Criteria:

• Life expectancy = 1 year
• Dissecting, ruptured, or leaking aneurysm (blood outside the aorta), has sustained recent trauma, is symptomatic, or is non-degenerative
• Aneurysm is thoraco-abdominal, suprarenal and/or mycotic
• Thoracic aneurysm = 4.5cm in diameter
• AAA requires treatment that would result in bilateral occlusion of the internal iliac arteries
• Presence of mural thrombus > 50% circumferentially in aortic neck
• Iliac aneurysm blood lumen diameter > 35mm
• Active infection, vasculitis, or systemic connective tissue disease (e.g., Rheumatoid arthritis, scleroderma, Marfan's syndrome, Ehlers-Danlos disease) at time of procedure
• History of prior treatment of abdominal aortic or iliac artery aneurysm disease
• Femoral or iliac artery occlusive disease such that device delivery is not possible
• Vascular access for delivery of device requires placement of vascular conduit or is through an established vascular graft
• Receiving dialysis
• History of hypercoagulability
• Allergy to IV contrast
• Serum creatinine level >2.0 mg/dL (or equivalent)
• Patient is pregnant or nursing
• Patient is currently enrolled in an investigational drug or device trial

Related Conditions & MeSH terms

• Abdominal Aortic Aneurysms
• Aneurysm
• Aortic Aneurysm
• Aortic Aneurysm, Abdominal

Intervention

Device:
• The Nellix® EndoVascular Aneurysm Sealing System

Locations

Country	Name	City	State
Colombia	Centro Medico de Cali	Cali
Latvia	Paul Stradins University Hospital	Riga
New Zealand	Auckland City Hospital	Auckland
Venezuela	Instituto de Clinicas Y Urologica Tomanaco	Caracas

Sponsors (1)

Lead Sponsor	Collaborator
Endologix

Countries where clinical trial is conducted

Colombia,  Latvia,  New Zealand,  Venezuela, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety- Number of Major Adverse Events	The primary safety endpoint is defined as the incidence of Major Adverse Events (MAE) through 30 days after the index procedure.	30 day
Primary	Device Performance	The primary performance endpoint is technical success defined as successful delivery and deployment of the device and freedom from open surgical conversion at 30 days.	30 days
Secondary	All Cause Mortality	Any death occurring during the study period, regardless of cause	12 months